The Emerging Role of Paclitaxel in Breast Cancer Therapy

Clinical Cancer Research

Volumn 1, Issue 3, 1995, Pages 247-256

  Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MITOXANTRONE; PACLITAXEL;

BREAST CANCER; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMAN; MICE; MICE, NUDE; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION, HETEROLOGOUS;

EID: 0028904701     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Boring, C. C., Squires, T. S., Tong T., et al. Cancer statistics 1994. CA Cancer J. Clin., 44: 7–26, 1994.
2. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 1992.
3. Manfredi, J. J., and Horwitz, S. B. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther., 25: 83–125, 1984.
4. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111: 273–279, 1989.
5. Taxol Investigator Brochure, p. 11, August 1, 1994.
6. Zhan, Z., Kang, Y-K., Regis, J., et al. Taxol resistance: in vitro and in vivo studies in breast cancer and lymphoma. Proc. Am. Assoc. Cancer Res., 34: 215, 1993.
7. Zhan, Z., Kang, Y-K., Giannakakou, P., et al. Tubulin expression and polymerization in normal tissues, human tumors, and paclitaxel selected ovarian and breast carcinoma cell lines. Proc. Am. Assoc. Cancer Res., 35: 390, 1994.
8. Hahn, S. M., Liebmann, J. E., Cook, J., et al. Taxol in combination with doxorubicin or etoposide: possible antagonism in vitro. Cancer (Phila.), 72: 2705–2711, 1993.
9. Cook, J. A., Fisher J., Teague D., et al. Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells. Proc. Am. Assoc. Cancer Res., 35: 332, 1994.
10. Chou, T-C., Otter, G. M., Sirotnak, F. M., et al. Combined effects of edatrexate with taxol or taxotere against breast cancer cell growth. Proc. Am. Assoc. Cancer Res., 34: 300, 1993.
11. Hata Y, Sandler, A. B., Loehrer, P. J., et al. Gallium nitrate and paclitaxel are synergistic in breast and additive in ovarian carcinoma cells. Proc Am Assoc Cancer Res 35: 333, 1994.
12. Yeh, Y. A., Olah E, Wendel, J. J., et al. Schedule-dependent synergistic action of tiazofurin and paclitaxel in human breast carcinoma cells. Proc. Am. Assoc. Cancer Res., 35: 332, 1994.
13. Baselga, J., Norton, L., Masui, H., et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327–1333, 1993.
14. Baselga, J., Norton, L., Coplan, K., et al. Antitumor activity of paclitaxel in combination with anti-growth factor receptor antibodies in breast cancer xenografts. Proc. Am. Assoc. Cancer Res., 35: 380, 1994.
15. Holmes, F. A., Walters, R. S., Theriault, R. L., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797–1805, 1991.
16. Reichman, B. S., Seidman, A. D., Crown, J. P. A., et al. Taxol and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol., 11: 1943–1951, 1993.
17. Seidman, A. D., Norton, L., Reichman, B., et al. Preliminary experience with taxol plus recombinant human granulocyte colony stimulating factor in the treatment of breast cancer. Semin. Oncol. 20 (Suppl. 3): 40–45, 1993.
18. Seidman, A. D., Reichman, B. S., Crown, J. P. A., et al. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: Activity independent of prior anthracycline response. J. Clin. Oncol., in press, 1995.
19. Gelmon, K., Nabholtz, J. M., Bontenbal, M., et al. Randomized trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Annals of Oncology, Vol. 5, Suppl. 5, p. 198. Lugano, Switzerland: Kluwer Academic Publishers, 1994.
20. Seidman, A. D., Barrett, S., Hudis, C., et al. Three hour taxol infusion as initial and as salvage chemotherapy of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 66, 1994.
21. Capri, G., Munzone, E., Tarenzi, E., et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J. Natl. Cancer Inst., 86: 1099–1101, 1994.
22. Gianni, L., Kearns, C. M., Giani, A., et al. Non-linear pharmacokinetics, metabolism, and pharmacodynamics of paclitaxel in adult patients with solid tumors. J. Clin. Oncol., 13: 180–190, 1995.
23. Holmes, F. A., Valero, V., Theriault, R. L., et al. Phase II trial of taxol in metastatic breast cancer refractory to multiple prior treatments. Proc. Am. Soc. Clin. Oncol., 12: 94, 1993.
24. Adams, J. S., Vena, D. A., Baltz, J., et al. Paclitaxel (taxol) activity in heavily treated metastatic breast cancer. Proceedings of the 8th NCI-EORTC symposium on new drugs in cancer therapy, A494: 199, 1994.
25. Seidman, A. D., McCarthy, J., Anthony, V., et al. Pain and quality of life assessment in patients receiving taxol and recombinant human granulocyte colony stimulating factor for metastatic breast cancer. Proceedings of the 2nd NCI Workshop on Taxol and Taxus, Abstract 1–1. Alexandria, Virginia: U.S. National Cancer Institute, 1992.
26. Cella, D. F., Tulsky, D. S., Gray, G., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol., 11: 570–579, 1993.
27. Lopes, N. M., Adams, E. G., Pitts, T. W., et al. Cell kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32: 235–242, 1993.
28. Wilson, W. H., Berg, S. L., Bryant, G., et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol., 12: 1621–1629, 1994.
29. Hochhauser, D., Seidman, A. D., Gollub, M., et al. Efficacy of prolonged paclitaxel infusion after failure of prior short taxane infusion: a phase II and pharmacologic study in metastatic breast cancer. Proceedings of the 17th Annual San Antonio Breast Cancer Symposium (Abstract 24). Breast Cancer Res. Treat. 32: 24, 1994.
30. Dieras, V., Marty, M., Morvan, F., et al. A phase II randomized study of taxol versus mitomycin C in patients with advanced breast cancer: interim analysis. Proc. Am Soc. Clin. Oncol., 13: 112, 1994.
31. Fisherman, J. S., McCabe, M., Noone, M., et al. Phase I study of taxol, doxorubicin, plus granulocyte colony stimulating factor (G-CSF) in patients with metastatic breast cancer. Monogr. Natl. Cancer Inst., 15: 189–194, 1993.
32. Pestalozzi, B. C., Sotos, G. A., Choyke, P. L., et al. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer (Phila.), 71: 1797–800, 1993.
33. Holmes, F. A., Valero V, Walters, R. S., et al. The M. D. Anderson Cancer Center experience with taxol in metastatic breast cancer. Monogr. J. Natl. Cancer Inst., 15: 161–169, 1993.
34. Holmes, F. A., Newman, R. A., Madden, T., et al. Schedule dependent pharmacokinetics in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Annals of Oncology, Vol. 5, Suppl. 5, p. 197. Lugano, Switzerland: Kluwer Academic Publishers, 1994.
35. Sledge, G., Sparano, J., McCaskill-Stevens, W., et al. Pilot trial of alternating taxol and adriamycin for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 12: 71, 1993.
36. Sledge, G. W. Defining the roles of paclitaxel and doxorubicin in the treatment of breast cancer. Proceedings of the 8th International Congress on Senology, Rio de Janiero, Brazil, 1994.
37. Eisenhauer, E. A., Ten Bokkel Huinink, W. W., Swenerton, K., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J. Clin. Oncol., 12: 2654–2666, 1994.
38. Gianni, L., Straneo, M., Capri, G., et al. Optimal dose and sequence-finding study of paclitaxel (P) by 3h infusion combined with bolus doxorubicin (D) in untreated metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 74, 1994.
39. Tolcher, A., Cowan, K., Riley, J., et al. Phase I study of paclitaxel and cyclophosphamide and G-CSF in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 73, 1994.
40. Kennedy, M. J., Donehower, R. C., Sartorius, S. E., et al. Sequences of taxol and cyclophosphamide: a phase I and pharmacologic study in doxorubicin resistant metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 12: 165, 1993.
41. Pagani, O., Sessa, C., Goldhirsch, A., et al. Taxol and cyclophosphamide in patients with advanced breast cancer: a dose finding study with the addition of G-CSF. Proc. Am. Soc. Clin. Oncol., 13: 61, 1994.
42. Fennelly, D., Schneider, J., Spriggs, D. et al. Dose-escalation of Taxol with high-dose cyclophosphamide, with analysis of progenitor cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J. Clin. Oncol., in press, 1995.
43. Smith, I. E., and Talbot, D. C. Cisplatin and its analogues in the treatment of advanced breast cancer. Br. J. Cancer, 65: 787–793, 1992.
44. Wasserheit, C., Alter, R., Speyer, J., et al. Phase II trial of paclitaxel and cisplatin in women with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 100, 1994.
45. Gelmon, K., O’Reilly, S., Plenderleith, I. H., et al. Bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 71, 1994.
46. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol., 9: 1692–1703, 1991.
47. Elkordy, M., Matters, L., Coniglio, D., et al. The effect of continuous 5-FU with or without taxol as induction therapy in stage IV breast carcinoma. Proc. Am. Soc. Clin. Oncol., 13: 95, 1994.
48. Fennelly, D., Hudis, C., Seidman, A., et al. Phase I trial of sequential edatrexate followed by paclitaxel in patients with advanced breast cancer. Proceedings of the 17th Annual San Antonio Breast Cancer Symposium (Abstract 28). Breast Cancer Res. Treat., 32: 35, 1994.
49. Rosenthal, C. J., Ibrahim, A., Rambhia, H., et al. Paclitaxel (taxol)-mitoxantrone salvage therapy in metastatic carcinoma of the breast—phase I/II study. Proc. Am. Soc. Clin. Oncol., 13: 92, 1994.
50. Stemmer, S., Jones, R., Bearman, S., et al. Intensive taxol/cyclophosphamide/cisplatin with autologous hematopoietic support. Proc. Am. Soc. Clin. Oncol., 13: 222, 1994.
51. Choy, H., Rodriguez, F. F., Koester, S., et al. Investigation of taxol as a potential radiation sensitizer. Cancer (Phila.), 71: 3774-3778, 1993.
52. Gupta, R. S. Taxol resistant mutants of Chinese hamster ovary cells: genetic, biochemical, and cross-resistance studies. J. Cell. Physiol., 114: 137–144, 1983.
53. Roy, S. N., and Horwitz, S. B. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res., 45: 3856-3863,1985.
54. Kirschener, L. S., Greenberger, L. M., Hong Hsu, S. I., et al. Biochemical and genetic characterization of the multidrug resistant phenotype in murine macrophage-like J774.2 cells. Biochem. Pharmacol., 43: 77–87, 1992.
55. Racker, E., Wu, L-T., and Westcott, D. Use of slow Ca2+channel blockers to enhance inhibition by taxol of growth of drug-sensitive and -resistant Chinese Hamster ovary cells. Cancer Treat. Rep., 70: 275–278, 1986.
56. Jachez, B., Nordmann, R., and Loor, F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptide SDZ 280–446. J. Natl. Cancer Inst., 85: 478–483, 1993.
57. Webster, L., Linsenmeyer, M., Millward, M., et al. Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion by the multidrug-resistant phenotype. J. Natl. Cancer Inst., 85: 1685–1690, 1993.
58. Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnoeski, G. M., Williams, B., and Bertoncello, I. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res., 50: 4199–4203, 1990.
59. Hochhauser, D., and Harris, A. L. The role of topoisomerase IIα and β in drug resistance. Cancer Treat. Rev., 19: 181–194, 1993.
60. Tolcher, A., Cowan, K., Filey, J., et al. Phase I study of paclitaxel with r-verapamil in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 139, 1994.
61. Schibler, M. J., and Cabral, F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in a- and p-tubulin. J. Cell Biol., 102: 1522–1531, 1986.
62. Demetri, G. D., Berry, D., Younger, J., et al. Dose-intensified cyclophosphamide/doxorubicin followed by taxol as adjuvant systemic chemotherapy for node-positive breast cancer (CALGB 9141): randomized comparison of two dose levels of G-CSF. Proc. Am. Soc. Clin. Oncol., 13: 65, 1994.
63. Hudis, C., Lebwohl, D., Crown, J., et al. Dose intensive sequential crossover adjuvant chemotherapy for women with high risk node positive primary breast cancer. In: S. Salmon (ed.), Adjuvant Therapy of Cancer VII, pp. 214–219. Philadelphia: J. B. Lippincott Co., 1993.
64. Norton, L. Implications of kinetic heterogeneity in clinical oncology. Semin. Oncol., 12: 231, 1985.
65. Buzzoni, R., Bonadonna, G., Valagussa, P., et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J. Clin. Oncol., 9: 2134–2140, 1992.
66. Hudis, C., Seidman, A., Baselga, J., et al. Sequential high dose adjuvant doxorubicin, paclitaxel, and cyclophosphamide with G-CSF for women with resected breast cancer and > 4 (+) lymph nodes. Proc. Am. Soc. Clin. Oncol., 13: 65, 1994.
67. Dmitrov, N., Anderson, S., Fisher, B., et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: findings from NSABP B-22. Proc. Am. Soc. Clin. Oncol., 13: 64, 1994.
68. Seidman, A. D., Hudis, C., Crown, J. P. A., et al. Phase II evaluation of Taxotere (RP 56976, NSC628503) as initial chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 12: 63, 1993.
69. Fumoleau, P., Chevallier, B., Kerbrat, B., et al. First-line chemotherapy with Taxotere in advanced breast cancer: a phase II study of the EORTC Clinical Screening Group. Proc. Am. Soc. Clin. Oncol., 12: 56, 1993.
70. Trudeau, M. E., Eisenhauer, E., Lofters, W., et al. Phase II study of Taxotere as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Proc. Am. Soc. Clin. Oncol., 12: 63, 1993.
71. Fumoleau, P., Chevallier, B. Dieras, V., et al. Evaluation of two doses of taxotere (docetaxe) as first line in advanced breast cancer—EORTC Clinical Screening Group Report. Proceedings of the 17th Annual San Antonio Breast Cancer Symposium (Abstract 22). Breast Cancer Res. Treat., 32: 34, 1994.
72. Ten Bokkel Huinink, W. W., Prove, A. M., Piccart, M., et al. A phase II trial with doctaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer. Ann. Oncol., 5: 527–532, 1994.
73. Valero, V., Esparza, L., Holmes, F., et al. Phase II study of Taxotere in refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 12: 96, 1993.
74. Vermorken, J. The efficacy of high-dose paclitaxel in patients with advanced breast cancer refractory to anthracycline therapy. Proceedings of the 8th International Congress on Senology, Rio de Janiero, Brazil, 1994.
75. Apfel, S. C., Lipton, R. B., Arezzo, J. C., et al. Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol., 29: 87–90, 1991.
76. Gluck, S., Sharan, N., Chadderton, T., et al. In vitro combination of paclitaxel (taxol) with 5 different cytotoxic drugs: effect on three different cell lines. Proc. Am. Assoc. Cancer Res., 35: 335, 1994.
77. Geoffroy, F., Patel, M., Ren, Q-F., and Grem, J. Interaction of fluorouracil and paclitaxel in MCF-7 human breast carcinoma cells. Proc. Am. Assoc. Cancer Res., 35: 330, 1994.
78. Adams, D. J. Synergy of Navelbine-taxol combination treatment in two human breast cancer cell lines. Proc. Am. Assoc. Cancer Res., 35: 327, 1994.
79. Knick, V. C., Eberwin, D. J., and Miller, C. G. Preclinical activity of Navelbine and taxol drug combinations. Proc. Am. Assoc. Cancer Res., 35: 327, 1994.
80. Speicher, L. A., Barone, L., and Tew, K. D. Combined antimicro-tubule activity of estramustine and taxol in human prostatic cancer cell lines. Cancer Res., 52: 4433–4440, 1992.
81. Chou, T-C., Motzer, R. J., Tong, Y., and Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst., 86: 1517–1524, 1994.
82. Koechli, O. R., Sevin, B. U., Perras, J. P., et al. Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res. Treat., 28: 21–27, 1993.
83. Georgiadis, M. S., Russell, E., Johnson, B. E., et al. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity. Proc. Am. Assoc. Cancer Res., 35: 341, 1994.
84. Adler, L. M., Herzog, T. J., Williams, S., et al. Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer (Phila.), 74: 1891–1898, 1994.
85. Untch, M., Untch, A., Sevin, B. U., et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anti-Cancer Drugs, 5: 24–30, 1994.
86. Hainsworth, J. D., and Greco, F. A. Paclitaxel administered by 1-hour infusion: preliminary results of a phase I-II trials comparing two schedules. Cancer (Phila.), 74: 1377–1382, 1994.
87. Chin, A., Ramkrishnan, R. R., Yoshimura, N. N., et al. Paclitaxel stability and compatibility in polyolefin containers. Ann. Pharmacother., 28: 35–36, 1994.
88. Gehl, J., Ejlersen, B., Boesgaard, M., and Dombernovsky, P. Efficacy and toxicity of combined doxorubicin and paclitaxel in metastatic breast cancer (preliminary results) (Abstract 192). Ann. Oncol., 5 (Suppl. 8): 39, 1994.